Browse 11 Khavinson short-peptide bioregulators tracked on Peptigrity, with verified third-party HPLC purity data, shop coverage, and mechanism research for each. These compounds — developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology over four decades — are a distinct class from Western synthetic peptides. They are short peptides (2-4 amino acids) extracted from or modeled on animal organ tissue, proposed to act as gene-regulatory bioregulators. Most evidence is preclinical or from Russian-language clinical literature with limited Western replication.
Last updated: April 2026
Bioregulators are categorized by the organ system they were developed to support. Each compound was extracted from or designed to model peptides found in a specific tissue — the proposed mechanism is organ-specific gene expression modulation rather than systemic action.
Note: Epithalon is sometimes grouped with Khavinson bioregulators historically (it was developed by the same research program), but is tracked separately on Peptigrity under Immune Support & Longevity due to its distinct telomerase-activation research focus. See the Epithalon profile and the where to buy Epitalon guide for that compound.
Peptide bioregulators are short peptides — typically two to four amino acids long — proposed to regulate gene expression in specific tissues. The class was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the early 1970s with research into thymus-derived immunomodulators. Khavinson's framework holds that aging is partly a result of declining peptide-mediated regulatory signals in organ tissues, and that exogenously administered short peptides can restore organ-specific function by modulating gene transcription.
This framework has substantial Russian-language research backing and a distinct theoretical foundation, but limited Western peer-reviewed replication. Most evidence is preclinical (cell culture, animal models) or from Russian observational and clinical studies that haven't been reproduced in Western randomized controlled trials. For this reason, bioregulators occupy an unusual evidence position on Peptigrity: the compounds are real, the research program is real, but the standard of evidence Western readers expect from FDA-approved drugs does not currently apply to most claims about them.
Peptide bioregulators are short peptides — typically two to four amino acids long — proposed to regulate gene expression in specific tissues. The class was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the early 1970s with research into thymus-derived immunomodulators. Khavinson's framework holds that aging is partly a result of declining peptide-mediated regulatory signals in organ tissues, and that exogenously administered short peptides can restore organ-specific function by modulating gene transcription.
This framework has substantial Russian-language research backing and a distinct theoretical foundation, but limited Western peer-reviewed replication. Most evidence is preclinical (cell culture, animal models) or from Russian observational and clinical studies that haven't been reproduced in Western randomized controlled trials. For this reason, bioregulators occupy an unusual evidence position on Peptigrity: the compounds are real, the research program is real, but the standard of evidence Western readers expect from FDA-approved drugs does not currently apply to most claims about them.
## How bioregulators differ from Western peptides
Most peptides discussed in research peptide communities — BPC-157, GLP-1 receptor agonists, growth hormone secretagogues, melanocortin receptor agonists — operate through identifiable receptor mechanisms characterized in Western pharmacology. They bind to specific receptors, trigger downstream signaling cascades, and produce measurable physiological effects through well-mapped pathways.
Khavinson bioregulators do not have similarly characterized receptors. The proposed mechanism is gene transcription modulation: the peptide enters cells of its target tissue, interacts with DNA or chromatin, and modulates the expression of organ-specific proteins. This mechanism is supported by some Russian molecular biology research but has not been mapped at the resolution Western pharmacology requires for FDA approval of a drug. The receptor-target field is essentially "tissue genome, cell-type-specific" rather than a named receptor protein.
This distinction matters for buyers. Bioregulator effects are reported to develop slowly (over weeks to months) and to be subtle — closer to hormone replacement therapy in pacing than to acute pharmacological intervention. Users expecting BPC-157-like injury healing speed or GLP-1-like appetite suppression are reading the wrong evidence base.
## The Khavinson research program
Vladimir Khavinson, born 1946, is the founder and former director of the St. Petersburg Institute of Bioregulation and Gerontology, established 1992. His research program on tissue-specific peptide bioregulation began in the early 1970s under Soviet military medicine — initial work focused on thymus-extracted peptides for immune restoration in personnel exposed to ionizing radiation and chemical agents.
Over the following five decades, Khavinson and his collaborators published several hundred papers (most in Russian-language journals) characterizing short-peptide bioregulators for thymus, pineal gland, cardiovascular tissue, liver, pancreas, and other organ systems. The program produced both natural extracts (Thymalin) and synthetic short-peptide analogues (Vilon, Pinealon, Vesugen, etc.).
Several bioregulators are registered as drugs in the Russian Federation for specific clinical indications. None are FDA-approved in the United States, EMA-approved in Europe, or MHRA-approved in the United Kingdom. The replication gap between Russian and Western research is the central issue for evaluating these compounds: the body of evidence is real and substantial, but it sits outside the regulatory frameworks Western buyers are accustomed to.
## Evidence landscape
For most bioregulators in this category, the evidence pyramid looks roughly like this:
- Russian clinical and observational research: substantial, often spanning decades, but generally not replicated in Western controlled trials
- Western preclinical research: scattered, mostly mechanism-of-action studies in cell culture or animal models
- Western clinical trials: minimal to none for most compounds
- Independent purity verification: this is where Peptigrity's data adds unique value — verified HPLC and mass spec data on what's actually being sold under each compound name
When evaluating claims about bioregulators, the practical question is not "did Western RCTs confirm this?" — they generally haven't — but "does the Russian research base, plus the available preclinical literature, support this specific claim, and is the compound I'm buying actually what's on the label?"
## Why quality verification is particularly important here
Bioregulators are short peptides (2-4 amino acids), making them chemically simpler to synthesize than 15+ residue peptides like BPC-157 or 39-residue peptides like CJC-1295. This is good for authentic synthesis but also lowers the barrier for substitution and counterfeiting. Two specific risks apply: identity substitution (another short peptide sold under the bioregulator name) and total absence (the vial contains buffer or excipient with no active peptide). Mass spectrometry identity confirmation is non-optional.
Independent lab data on bioregulators is sparser than on flagship compounds like BPC-157 or tirzepatide because shop coverage is thinner. Several of the compounds in this category are tracked by very few or no shops on Peptigrity. The compound pages above show current shop counts and lab test counts.
For deeper background on peptide chemistry and how short peptides are manufactured, see how peptides are made. For verification methodology, see how to read peptide lab test results.
Bioregulators are short peptides (2-4 amino acids), and the risk profile differs from longer peptides:
IDENTITY SUBSTITUTION: Short peptides are easy to substitute for one another. A vial labeled "Vilon" (Lys-Glu) could contain a different dipeptide entirely without obvious differences in physical appearance. Mass spectrometry confirmation of the exact molecular weight is the only reliable identity check.
ABSENT-COMPOUND VIALS: Because Western shop coverage of bioregulators is thin and demand is small, some vendors sell low-volume products with minimal manufacturing oversight. Independent third-party HPLC testing catches vials that contain no active peptide.
THIN INDEPENDENT DATA: Some bioregulators on this page have very few verified lab tests on Peptigrity (visible in the per-compound test counts above). For those compounds, the absence of test data is itself information — fewer independent checks means more vendor trust required.
No. None of the 11 bioregulators tracked on Peptigrity are FDA-approved in the United States, EMA-approved in Europe, or MHRA-approved in the United Kingdom. Several are registered as drugs in the Russian Federation for specific clinical indications. In Western jurisdictions, all are research compounds.
→ See country-specific peptide regulatory status: /blog/are-peptides-legal-regulatory-status-by-country
No. None of the 11 bioregulators tracked on Peptigrity are FDA-approved in the United States, EMA-approved in Europe, or MHRA-approved in the United Kingdom. Several are registered as drugs in the Russian Federation for specific clinical indications. In Western jurisdictions, all are research compounds.
→ See country-specific peptide regulatory status: /blog/are-peptides-legal-regulatory-status-by-country
The class was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology starting in the 1970s, primarily under Soviet and later Russian government research programs. Most clinical and preclinical work has been published in Russian-language journals. Western pharmaceutical research has not prioritized replication, partly because the proposed mechanism (tissue-specific gene transcription modulation by short peptides) does not fit neatly into the receptor-target framework Western drug development relies on. The replication gap is the central evidence question for this class.
The class was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology starting in the 1970s, primarily under Soviet and later Russian government research programs. Most clinical and preclinical work has been published in Russian-language journals. Western pharmaceutical research has not prioritized replication, partly because the proposed mechanism (tissue-specific gene transcription modulation by short peptides) does not fit neatly into the receptor-target framework Western drug development relies on. The replication gap is the central evidence question for this class.
Thymalin has the longest research history — Khavinson's group began publishing on thymus-derived peptide bioregulators in the 1970s. It is also the only compound in this category that is a polypeptide complex extracted from animal tissue rather than a synthetic short peptide. Pinealon and Vilon have moderate Russian research bases. The remaining bioregulators have thinner published evidence, mostly in Russian-language journals.
Thymalin has the longest research history — Khavinson's group began publishing on thymus-derived peptide bioregulators in the 1970s. It is also the only compound in this category that is a polypeptide complex extracted from animal tissue rather than a synthetic short peptide. Pinealon and Vilon have moderate Russian research bases. The remaining bioregulators have thinner published evidence, mostly in Russian-language journals.
No. Bioregulators are a separate class from Western research peptides in mechanism, evidence base, and regulatory history. BPC-157 and TB-500 are tissue-repair peptides with characterized angiogenesis and cytokine modulation mechanisms. GLP-1 peptides act on a specific G-protein-coupled receptor. Bioregulators operate through proposed gene-expression modulation in target tissues, do not have characterized receptor targets in the Western sense, and develop their effects on a slower (weeks-to-months) timescale than the acute peptides Western buyers may be familiar with.
No. Bioregulators are a separate class from Western research peptides in mechanism, evidence base, and regulatory history. BPC-157 and TB-500 are tissue-repair peptides with characterized angiogenesis and cytokine modulation mechanisms. GLP-1 peptides act on a specific G-protein-coupled receptor. Bioregulators operate through proposed gene-expression modulation in target tissues, do not have characterized receptor targets in the Western sense, and develop their effects on a slower (weeks-to-months) timescale than the acute peptides Western buyers may be familiar with.
No. The evidence available for bioregulators is structurally different from the evidence base for FDA-approved peptides like semaglutide or tirzepatide, which have undergone large Phase 3 randomized controlled trials in tens of thousands of patients. Bioregulator evidence is largely Russian clinical and observational data plus Western preclinical research. This is not "no evidence" — but it is not equivalent to RCT-grade evidence either. Buyers should evaluate claims against the actual Russian and preclinical literature for each specific compound rather than against the Western FDA-trial standard.
No. The evidence available for bioregulators is structurally different from the evidence base for FDA-approved peptides like semaglutide or tirzepatide, which have undergone large Phase 3 randomized controlled trials in tens of thousands of patients. Bioregulator evidence is largely Russian clinical and observational data plus Western preclinical research. This is not "no evidence" — but it is not equivalent to RCT-grade evidence either. Buyers should evaluate claims against the actual Russian and preclinical literature for each specific compound rather than against the Western FDA-trial standard.
Yes. Third-party HPLC and mass spectrometry testing applies to bioregulators the same as to any peptide. The compound list above shows current verified test counts for each bioregulator on Peptigrity. If a compound has zero or very few tests, you can submit a sample for independent testing — the resulting data adds to the public verification record.
→ How to get your peptides independently tested: /blog/how-to-get-your-peptides-independently-tested
→ Submit a lab test: /add/lab-test
Yes. Third-party HPLC and mass spectrometry testing applies to bioregulators the same as to any peptide. The compound list above shows current verified test counts for each bioregulator on Peptigrity. If a compound has zero or very few tests, you can submit a sample for independent testing — the resulting data adds to the public verification record.
→ How to get your peptides independently tested: /blog/how-to-get-your-peptides-independently-tested
→ Submit a lab test: /add/lab-test